Inclusion Criteria:

          -  Histologically confirmed melanoma of cutaneous origin

          -  Participants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic
             Stage IIC or Stage III according to AJCC Staging Criteria version 7 that has been
             completely resected

          -  BRAF V600 mutation status of the current primary tumor or involved lymph node
             determined to be positive using the cobas BRAF V600 mutation test

          -  Surgically rendered free of disease within 90 days of randomization

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy of at least 5 years

          -  Fully recovered from the effects of any major surgery or significant traumatic injury
             prior to the first dose of study treatment

          -  Adequate hematologic, hepatic, and renal function

        Exclusion Criteria:

          -  History of any systemic or local therapy (e.g., chemotherapy, biologic or targeted
             therapy, hormonal therapy, or photodynamic therapy) for the treatment or prevention of
             melanoma, including interferon alpha-2b and pegylated interferon alpha-2b

          -  History of limb perfusion therapy

          -  History of radiotherapy for the treatment of melanoma

          -  Invasive malignancy other than melanoma at the time of enrollment or within 5 years
             prior to first dose of study treatment

          -  Family history of inherited colon cancer syndromes

          -  Known personal history of >3 adenomatous colorectal polyps or a personal history of
             adenomatous colorectal polyp(s) >2 centimeters (cm) in size

          -  History of or current clinical, radiographic, or pathologic evidence of in-transit
             metastases, satellite, or microsatellite lesions

          -  History of or current clinical, radiographic, or pathologic evidence of recurrent
             lymph node involvement after resection of a primary melanoma with lymph node
             involvement at any time in the past

          -  History of local and/or regional and/or distant melanoma recurrence

          -  History or current radiographic or pathologic evidence of distant metastases

          -  History of clinically significant cardiac or pulmonary dysfunction

          -  Major surgical procedure or significant traumatic injury within 4 weeks prior to first
             dose of study treatment

          -  Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus